Europe In Vitro Diagnostics Market to USD 44.12 Billion by 2034 with a Robust CAGR of 4.90%

The Europe in vitro diagnostics market is experiencing robust growth, driven by an ageing population, a high prevalence of chronic diseases, the implementation of the new EU In Vitro Diagnostic Regulation (IVDR) 2017/746, and the rise of precision medicine. The market size increased from USD 28.69 Billion in 2025 to USD 30.09 Billion in 2026 and is projected to reach USD 44.12 Billion by 2034, expanding at a compound annual growth rate (CAGR) of 4.90% during the forecast period (2026-2034) . This growth is underpinned by the COVID-19-era surge in rapid testing demand, which has structurally expanded the market for molecular and point-of-care diagnostics.

In vitro diagnostics (IVD) encompasses a wide range of tests, instruments, reagents, and software used to examine biological specimens from the human body to diagnose diseases, monitor treatments, and guide therapeutic decisions. The European IVD ecosystem includes major multinational manufacturers, extensive clinical laboratory networks, and a rapidly growing point-of-care testing (POCT) and digital diagnostics sector . Key applications span clinical chemistry, molecular diagnostics, immunodiagnostics, and microbiology, with demand fueled by healthcare expenditure trends, research funding, and demographic shifts across the region.

Request a Sample Report for In-Depth Market Insights: https://www.imarcgroup.com/europe-in-vitro-diagnostics-market/requestsample

Europe In Vitro Diagnostics Market Summary

• Covers the market by test type (clinical chemistry, molecular diagnostics, immunodiagnostics, hematology), product (reagents and kits, instruments), usability (disposable IVD devices, reusable IVD devices), application (infectious disease, diabetes, cancer/oncology, cardiology, autoimmune disease), end user (hospitals laboratories, clinical laboratories, point-of-care testing centers, patients), and country (Germany, France, United Kingdom, Italy, Spain, Others) .

• The EU IVDR 2017/746 is a dominant regulatory theme, requiring manufacturers to reclassify over 90% of CE-marked IVDs into higher-risk classes and invest heavily in clinical performance studies, thereby elevating product quality and market access barriers .

• A significant shift towards precision medicine is underway, with molecular diagnostics and companion diagnostics expanding rapidly to enable targeted therapies, particularly in oncology, where the EMA approved 48 new active substances requiring a companion diagnostic in 2024 .

• The decentralization of testing is a key trend, with point-of-care platforms and self-testing kits gaining traction, driven by the need for rapid results, infection control, and patient convenience, especially in primary care and home settings .

PORTER'S FIVE FORCES ANALYSIS -- Europe In Vitro Diagnostics Market

The competitive dynamics of the Europe in vitro diagnostics market can be analyzed using Porter's Five Forces framework.

Porter's Five Forces Analysis -- Europe In Vitro Diagnostics Market

• Competitive Rivalry: High, characterized by intense competition among a few dominant global players, including F. Hoffmann-La Roche, Siemens Healthineers, and Abbott, which collectively command approximately 45-50% of the market revenue. Rivalry is driven by the need for continuous innovation, regulatory compliance (IVDR), and expansion into high-growth segments like molecular diagnostics and POCT. Business implication: Competitors must differentiate through comprehensive reagent menus, integrated automation solutions, and strong relationships with hospital networks and laboratory chains.
• Supplier Power (Component and Technology Providers): Moderate. While large OEMs have significant bargaining power over suppliers of standard components, providers of specialized technologies such as high-purity antibodies, enzymes, and AI-driven software hold increasing influence. The push for digital diagnostics and advanced platforms gives specialized tech suppliers a competitive edge. Business implication: OEMs must form strategic partnerships with technology firms or develop in-house capabilities to secure critical components and maintain a competitive advantage in digital and AI-powered diagnostics .
• Buyer Power (Hospitals, Laboratories, and Healthcare Systems): Moderate to High, particularly for large, consolidated laboratory networks that purchase in bulk. These buyers have significant negotiating power and can demand favorable pricing and terms. Laboratory consolidation across Europe is reducing the number of procurement decision-makers while increasing their purchasing power . However, smaller hospitals and individual clinics often have less power. Business implication: Manufacturers need to offer integrated solutions, flexible financing, and value-added services like data management and AI-assisted interpretation to secure large contracts and build long-term customer loyalty.
• Threat of Substitutes: Low to Moderate. The primary substitute for new IVD products is the use of used or refurbished equipment, which represents a cost-effective alternative for budget-constrained laboratories. In some cases, manual or less advanced testing methods can substitute for automated high-throughput systems, but this is increasingly uneconomical and less accurate due to rising labor costs and the need for efficiency. Business implication: To counter the threat, OEMs can focus on offering advanced technology, such as AI-powered decision support and syndromic panel testing, that provides clear efficiency and diagnostic accuracy advantages over older or less sophisticated methods .
• Threat of New Entrants: Moderate. High barriers exist for large-scale manufacturing due to the need for significant capital investment, established distribution networks, and strong brand reputation. However, barriers are lower for niche specialists, technology providers, or manufacturers of specific test types (e.g., rapid tests, AI software). The region's growth and focus on innovation attract new domestic and international entrants. Business implication: Established players should build defensible positions through technological leadership, a broad regulatory-compliant product portfolio, and strong relationships with key healthcare providers and distributors.

MARKET GROWTH DRIVERS

Ageing European Population Driving Chronic Disease Test Volumes

The number of individuals aged 60 and above in the WHO European Region is increasing significantly, rising from 215 million in 2021 to an estimated 247 million by 2030. This demographic shift directly correlates with higher demand for diagnostic tests for chronic conditions like cancer, cardiovascular diseases, and diabetes, which are prevalent in older populations and require routine screening and monitoring .

EU IVDR 2017/746 Quality Upgrade Cycle Creating Capital Investment Wave

The new EU In Vitro Diagnostic Regulation is forcing Europe's 2,200+ registered IVD manufacturers to invest heavily in clinical performance studies, Notified Body conformity assessments, and post-market surveillance systems. This regulatory shift is generating a significant capital expenditure cycle as manufacturers upgrade their products and quality management systems to meet higher standards .

Precision Medicine and Companion Diagnostics Expanding Oncology IVD

The growing emphasis on personalized medicine is driving demand for molecular diagnostics and companion diagnostics. These tests are essential for identifying patients who will benefit from specific targeted therapies. With the EMA approving numerous new cancer drugs requiring a companion diagnostic, this segment is poised for substantial growth .

Point-of-Care Testing Decentralization

The COVID-19 pandemic accelerated the adoption of POCT, and this trend has continued as healthcare systems seek to reduce hospital burdens and provide faster, more accessible testing. POCT platforms are expanding into primary care, pharmacies, and patient homes, creating a structural expansion of the testing market and increasing demand for disposable testing devices .

EUROPE IN VITRO DIAGNOSTICS MARKET SEGMENTATION

Test Type Insights:

• Clinical Chemistry (e.g., metabolic, liver, renal function tests)

• Molecular Diagnostics (e.g., PCR, NGS)

• Immunodiagnostics (e.g., ELISA, CLIA)

• Hematology (e.g., CBC, coagulation)

• Others

Product Insights:

• Reagents and Kits (e.g., immunoassay reagents, molecular consumables)

• Instruments (e.g., automated analyzers, PCR platforms, digital pathology scanners)

Usability Insights:

• Disposable IVD Devices (e.g., single-use test strips, sample collection tubes)

• Reusable IVD Devices (e.g., laboratory analyzers, scanners)

Application Insights:

• Infectious Disease

• Diabetes

• Cancer/Oncology

• Cardiology

• Autoimmune Disease

• Others

End User Insights:

• Hospitals Laboratories

• Clinical Laboratories

• Point-of-Care Testing Centers

• Patients (Self-testing)

• Academic & Research Institutes

Country Insights:

• Germany

• France

• United Kingdom

• Italy

• Spain

• Others

COMPETITIVE LANDSCAPE

The Europe in vitro diagnostics market features a highly concentrated competitive landscape led by major global players, with companies differentiating through broad product portfolios, automation capabilities, regulatory compliance, and digital health integration. Investment in molecular diagnostics, POCT, and AI-powered solutions is becoming a key competitive lever as the demand for precision and decentralization grows. The market is also seeing significant consolidation as large players acquire smaller innovators to fill platform gaps.

REGIONAL ANALYSIS

Germany:

Germany leads the European IVD market with an 18.0% market share (2025). Its dominance is driven by the most comprehensive statutory health insurance (GKV) laboratory reimbursement system in Europe, covering over 90% of the population without prior authorization. It is also home to major players like Siemens Healthineers and QIAGEN, and hosts Europe's most advanced diagnostic innovation infrastructure .

France:

France holds a 16.8% market share, benefiting from the presence of bioMérieux, the world's leading clinical microbiology company, and a robust healthcare system. The French national cancer plan is driving oncology IVD, and the Haute Autorité de Santé (HAS) is expanding reimbursement for precision medicine .

United Kingdom:

The UK accounts for 15.6% of the market, propelled by the NHS Genomics Medicine Service (GMS), which provides whole genome sequencing for over 100,000 patients annually. The legacy of the NHS Test and Trace program has also significantly expanded the country's diagnostic infrastructure .

Italy:

Italy holds a 14.4% share, with growth driven by the modernization of the Italian National Health Service (SSN). The country is investing in laboratory automation and benefits from the Istituto Superiore di Sanità (ISS) for infectious disease surveillance .

Spain:

Spain accounts for 12.8% of the market and is the fastest-growing major country at a CAGR of ~5.2% (2026-2034). Growth is driven by the Spanish national oncology genomics strategy and post-COVID POCT infrastructure expansion in primary care .

Key players include :

• F. Hoffmann-La Roche Ltd.

• Siemens Healthineers AG

• Abbott

• bioMérieux

• QIAGEN

• Danaher Corporation (Beckman Coulter, Cepheid)

• Thermo Fisher Scientific Inc.

• Sysmex Corporation

• Becton, Dickinson and Company

• Werfen

RECENT INDUSTRY DEVELOPMENTS

February 2026: Roche inaugurated its new Diagnostics Innovation Center in Penzberg, Germany, signifying a major investment in R&D and a commitment to leading the next generation of diagnostic innovation in Europe .

January 2026: Siemens Healthineers opened a new Immunoassay Instrument R&D Centre of Excellence in Swords, Ireland, backed by over €10 million in investment, to support innovation in laboratory diagnostics for infectious diseases, cancer, and blood disorders .

2025: The European Commission granted phased deadlines for IVDR compliance to ensure a more manageable transition for manufacturers and Notified Bodies, while still upholding the regulation's high-quality standards .

Note: If you need any specific information that is not covered currently within the scope of the report, we will provide the same as a part of customization.

Speak to an analyst: https://www.imarcgroup.com/request?type=report&id=11054&flag=C

About Us -

• Report Format, Delivery, and Customization Details
• Report Format Mode: PPT, PDF, and Excel
• Report Delivery Mode: Online Delivery, Physical Delivery
• Report Delivery Time: Report Delivered Over Email within 24 to 48 hours. If requested by the client, a physical copy will be delivered within three to ten days.
• Report Confirmation Mode: Yes via Email
• Report Customization Mode: Yes via Email / Call
• Report Table of Content: Yes
• Report List of Figures: Yes
• Report Methodology Mode: Yes
• Request For Sample Report: Yes

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St., Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201-971-6302